SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: dr_elis who wrote (7642)1/2/2003 9:08:34 AM
From: Biomaven  Respond to of 52153
 
<Antegren>

I don't think CATG is involved at all. I believe PDLI gets a (probably very low) royalty on Antegren because of PDLI's patents. Similar to the arrangements for Herceptin and Synagis.

Peter



To: dr_elis who wrote (7642)1/2/2003 9:46:51 AM
From: nigel bates  Read Replies (1) | Respond to of 52153
 
CATG does have a development collaboration with ELN, but nothing has hit the clinic yet.
In any event, CAT's MABs are supposed to be 'fully human' ab initio.

nig


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News